NASDAQ$CDNA
CareDx Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
CareDx's first quarter of 2023 saw a mix of record achievements and challenges, with revenue impacted by billing article revisions and strategic adjustments.
CareDx reported a decrease in revenue due to billing article revisions, which impacted AlloSure Kidney Medicare tests. Despite this, the company achieved record patient test results for AlloMap and AlloSure, and record revenue for its Patient and Digital Solutions business. The company is withdrawing its 2023 revenue guidance due to uncertainties related to billing article revisions.
- Delivered approximately 49,900 AlloMap and AlloSure patient test results, a 17% year-over-year increase.
- Reported revenue of $77.3 million, a 3% decrease year-over-year, which excludes $8.9 million in revenue associated with Impacted March Tests.
- Achieved record revenues of $8.6 million for the Patient and Digital Solutions business, a 39% year-over-year increase.
- Maintained a strong balance sheet with $285.9 million in cash and cash equivalents and marketable securities, and generated $0.7 million in net cash from operating activities.
Headline financials
Revenue & EPS history
CareDx · Revenue · Quarterly
$77.3M
Revenue by segment
CareDx · $68.6M total across 2 segments · Q1 2023
- Testing Services$61.8M-7.0%90.0%
- Product Revenue$6.86M+1.1%10.0%
Forward guidance
CareDx is withdrawing 2023 revenue guidance due to uncertainties related to the March and May 2023 Billing Article revisions.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
+2.4%
Avg return
Earnings day
+0.1%
Avg return
5 days after
+7.1%
Avg return
30 days after
54%
28 / 52 earnings
Positive
+45.7%
Q1 2024
Best reaction
-24.3%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.3% | -1.6% | +3.8% | |
| Q4 2025 | -4.3% | -2.6% | -12.8% | |
| Q3 2025 | -1.8% | +5.8% | +31.4% | |
| Q1 2025 | -10.7% | -16.0% | +0.7% | |
| Q4 2024 | -0.2% | -3.8% | -14.9% | |
| Q3 2024 | +1.1% | +4.5% | +14.5% | |
| Q2 2024 | +25.7% | +26.3% | +63.8% | |
| Q1 2024 | +45.7% | +49.7% | +49.4% | |
| Q4 2023 | +12.1% | +27.3% | +11.6% | |
| Q3 2023 | +8.7% | +19.5% | +48.0% | |
| Q2 2023 | -9.3% | -17.6% | -23.5% | |
| Q1 2023 | -2.0% | -2.2% | -8.7% | |
| Q4 2022 | +16.4% | -37.9% | -37.0% | |
| Q3 2022 | -16.5% | -14.4% | -31.1% | |
| Q2 2022 | +7.7% | -4.2% | -25.2% | |
| Q1 2022 | -24.3% | -32.1% | -23.9% | |
| Q4 2021 | +10.3% | +7.2% | +6.6% | |
| Q3 2021 | -24.3% | -26.9% | -37.1% | |
| Q2 2021 | -2.5% | -4.9% | -7.4% | |
| Q1 2021 | -1.9% | -10.0% | +9.3% | |
| Q4 2020 | +2.7% | +13.2% | -20.3% | |
| Q3 2020 | -3.1% | -2.4% | +13.5% | |
| Q2 2020 | +5.2% | -0.9% | -4.3% | |
| Q1 2020 | -0.0% | +9.6% | +19.6% | |
| Q4 2019 | -5.6% | -13.2% | -11.5% | |
| Q3 2019 | -11.8% | -23.8% | -21.6% | |
| Q2 2019 | +6.8% | -15.7% | -30.4% | |
| Q1 2019 | +15.0% | +12.6% | +30.6% | |
| Q4 2018 | +7.5% | +10.2% | -10.1% | |
| Q3 2018 | -9.8% | -10.2% | -6.0% | |
| Q2 2018 | +15.3% | +14.6% | +73.1% | |
| Q1 2018 | -2.1% | -2.6% | +35.1% | |
| Q4 2017 | +24.1% | +28.5% | +51.8% | |
| Q3 2017 | +6.2% | +6.6% | +31.0% | |
| Q2 2017 | +9.2% | +26.8% | +109.9% | |
| Q1 2017 | -4.6% | -3.7% | +14.7% | |
| Q4 2016 | +5.1% | -12.2% | +13.7% | |
| Q3 2016 | +1.3% | +3.9% | -24.7% | |
| Q2 2016 | -1.0% | -2.9% | -5.3% | |
| Q1 2016 | +6.0% | — | — | |
| Q4 2015 | +7.7% | — | — | |
| Q3 2015 | +5.0% | — | — | |
| Q2 2015 | -1.6% | — | — | |
| Q1 2014 | -0.4% | — | — | |
| Q1 2015 | -0.8% | — | — | |
| Q4 2012 | +0.5% | — | — | |
| Q4 2014 | -1.8% | — | — | |
| Q3 2013 | -1.0% | — | — | |
| Q3 2014 | +17.2% | — | — | |
| Q2 2013 | +0.2% | — | — | |
| Q4 2013 | +0.2% | — | — | |
| Q2 2014 | +1.9% | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro